^
Association details:
| Biomarker: | CRY1 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | PD1 inhibitor + CTLA4 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
5197 - Alterations of the circadian clock genes and their association with tumor mutation burden and response to immunotherapy in NSCLC
Published date:
03/09/2022
Excerpt:
The ICIs treatment NSCLC cohort from the Memorial Sloan Kettering Cancer Center (MSKCC) was used for exploring the associations of mutations in the clock genes (CLOCK, BMAL1, CRY1, CRY2, PER1, PER2, and PER3) with TMB, tumor neoantigen burden (TNB), and ICIs efficacy....Compared to the WT group, patients in the MT group had a significantly longer median progression-free survival (PFS) (23.0 vs 5.2 months, HR: 0.45 [95%CI: 0.25-0.81], P = 0.0216) with PD-1 plus CTLA-4 blockade.
